

STUDY PROTOCOL

Open Access

Rationale and design of the *CAPAMIS* study: Effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke

Angel Vila-Corcoles¹, Inmaculada Hospital-Guardiola¹, Olga Ochoa-Gondar^{1*}, Cinta de Diego¹, Elisabet Salsench¹, Xavier Raga², Cruz M Fuentes-Bellido^{1,3}

Abstract

Background: The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years.

Methods/Design: Cohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness.

Discussion: The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the possible role of pneumococcal vaccination in cardiovascular prevention.

Background

Epidemiology of pneumococcal infections

Infections caused by *Streptococcus pneumoniae* remain a major public health problem throughout the world. Susceptibility to pneumococcal infections varies with age, being highest in young children and older adults, who experience substantial morbidity and mortality

(especially in those with underlying high-risk medical conditions) [1,2].

The main reservoir of pneumococcus is the nasopharynx, and the possible outcomes after colonisation are the clearance by the organism, the asymptomatic persistence for several months (carrier state), or the progression to disease. During the disease the bacteria can spread to adjacent mucosal tissues causing mucosal infections (otitis, sinusitis, bronchitis and pneumonias) or it can invade the bloodstream, or other sterile sites, producing an invasive pneumococcal disease (IPD). In adults, *S. pneumoniae* is the most frequent isolate from

* Correspondence: oochoa.tarte.ics@gencat.cat

¹Primary Care Service of Tarragona-Valls, Institut Català de la Salut, Tarragona, Spain

clinical samples of respiratory tract infections. It is responsible for approximately 50% of overall cases of community-acquired pneumonia (CAP) in different populations [3-5].

Pneumococcal vaccination

In the last decades, the need for preventive strategies has driven multiple efforts to develop an effective vaccine, however the existence of more than 90 distinct pneumococcal serotypes has largely complicated the development and evaluation of anti-pneumococcal vaccines. To date, only a 23-valent polysaccharide pneumococcal vaccine (PPV-23) for use in adults and a 7-valent conjugate vaccine for use in infants are available in clinical practice [6-9].

The PPV-23 is generally recommended for high-risk and elderly individuals, but its effectiveness (despite numerous meta-analyses) remains controversial [10-19]. It has been demonstrated that PPV-23 provides considerable protection against invasive pneumococcal disease, while a possible protective effect against pneumonia is discussed [20]. The latest Cochrane Systematic Review supports the use of PPV to prevent IPD in adults, particularly in healthy adults, but it concluded that the meta-analysis does not provide compelling evidence to support the routine use of PPV to prevent pneumonia [18].

Epidemiological link between pneumonia and acute vascular events

For several decades, there has been data that chronic inflammation can promote atherosclerotic disease,[21] and in recent years some studies have also found data supporting the fact that acute infections (especially influenza and pneumonia) are associated with a transient increasing risk of acute vascular events [22-25]. In fact, it has been reported that a combination of the diagnosis of pneumonia and myocardial infarction is relatively common among patients hospitalised with severe pneumonia [24,25]. Thus, given this data, it has been suggested that pneumococcal vaccination could perhaps protect patients from cardiovascular events [26-28].

Following this, a recent case-control study conducted in Canada has reported a 47% reduction in the risk of acute myocardial infarction (AMI) among subjects who had received the PPV-23, however, the possible cardioprotective effect of pneumococcal vaccination has not still been proved [26].

Theoretically, pneumococcal vaccination could protect against acute cardiovascular events by an indirect effect preventing pneumonia (as the latter has been shown to trigger myocardial infarction), although a direct effect of pneumococcal vaccination on oxidized low-density lipoproteins can not be excluded. In fact, animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions and it has been hypothesized that antibodies directed against

Streptococcus pneumoniae would also recognize oxidized low-density lipoprotein and impede the formation of foam cells [29].

The possible effectiveness of PPV-23 to prevent myocardial infarction, if it exists, probably has been overestimated in the aforementioned Canadian report; however, given the prevalence of heart disease worldwide, even a modest protective effect (epidemiologically plausible) would translate into a considerable benefit at the population level [30]. Thus, prospective validations (which will determine whether the cardioprotective effect of vaccination is real and better estimate its true protective efficacy) are greatly needed.

Use of pneumococcal vaccine in the study area

In Catalonia, a region in the northeast of Spain with a population of seven million people, a publicly funded anti-pneumococcal vaccination programme for all individuals 65 years or older (with or without risk factors) and younger individuals with certain high-risk conditions (basically immunodeficiency, chronic heart or pulmonary disease, diabetes mellitus, severe liver disease or chronic nephropathy) began in October 1999. Further, it was extended for all people 60 years or older in 2002. Since then, a free PPV-23 has been offered when the patients came to the primary care services during the annual influenza vaccination campaigns or in any other visit throughout the year. Some years later, vaccination uptake reached approximately fifty percent,[31] and this provided an excellent opportunity to evaluate the vaccine's effects among the population. The potential effects of vaccination in preventing IPD and pneumonia have been analyzed in our reference population in two prior studies [32,33].

This project proposes a large population-based cohort study with the major aim of evaluating the clinical effectiveness of the PPV-23 against CAP as well as evaluating its potential role in cardiovascular prevention among the general population over 60 years.

Objectives of the capamis study

The primary objective of the planned study entitled *CAPAMIS* is to evaluate the clinical effectiveness of the PPV-23 in the prevention of a first episode of **Community-Acquired Pneumonia, Acute Myocardial Infarction and Stroke** among the general population over 60 years. Furthermore, the study will evaluate the effectiveness of PPV-23 in reducing the risk of secondary acute vascular events related with prior pneumonia.

Additional objectives include the evaluation of vaccination effectiveness against severity outcomes (including death, need of ICU admission or length of stay in hospital).

Furthermore, a detailed analysis on population-based data on incidence of myocardial infarction and stroke

will be performed in different subsets of the population with certain underlying conditions in order to establish, if it exists, the magnitude of vaccination effectiveness in primary and/or secondary cardiovascular prevention.

In addition to these objectives, the clinical effectiveness of revaccination against different outcomes will be evaluated in the subset of participants who have received more than a dose of PPV-23 prior to the study start or during the study period.

Methods and Design

Design, setting and study population

Population-based cohort study focused on adults over 60 years in the region of Tarragona, a mixed residential-industrial urban area in the Mediterranean coast of Catalonia, Spain.

Study subjects include 27,000 community-dwelling adults aged 60 years or more assigned to 9 participating Primary Care Centres (PCCs) in the study area, who will be followed during a 30-month consecutive period. Six of the nine participating PCCs are located in Tarragona city (PCC Bonavista, PCC Torreforta, PCC Jaume I, PCC Sant Pere i Sant Pau, PCC Tarraco, PCC Sant Salvador) and three PCCs are located in nearby (less than 12 kilometres from Tarragona) smaller municipalities (PCC Salou, PCC Constanti and PCC Morell). Two reference hospitals for the study population are Hospital Joan XXIII and Hospital Santa Tecla, both located in Tarragona city (which has an overall population of approximately 120,000 all-age inhabitants).

It must be noted that, in Spain, primary care physicians are the first point of call for secondary and tertiary care and all citizens are registered in one PCC.

Inclusion criteria for the CAPAMIS cohort include: a) male or female adults aged 60 years or older as of January 1, 2009; and b) registered in any of the nine PCCs participating at study start. Exclusion criteria include residence in a long-term care facility. Subjects will be identified from primary care information systems. Figure 1 shows the study region and illustrates the location of participating centres.

Cohort members will be followed from the beginning of the study (1 January 2009) until occurrence of the first event, the enrolment from the PCC ceases, death, or until the end of the study (30 June 2011).

Rationale for sample size

The annual incidence of CAP in older adults in the study area is estimated at approximately 10 per 1000 person-year based on prior population-based studies among elderly people in the same study area [34,35]. Incidences of AMI and stroke are estimated in 8 and 12 cases per 1000, respectively, in Spanish population [36,37]. Thus, considering a pneumococcal vaccine coverage of approximately 50%, [31] with a $p = 0.05$ (two-

tailed) the size of the study cohort ($N = 27,000$ individuals followed during a 30-month period) has an statistical power of 80% to detect a possible vaccination effectiveness of 20% against CAP, a 23% against AMI, a 18% against stroke and a 14% against the combined end-point AMI/stroke.

Data sources

All participating PCCs have a computerized clinical record system that includes administrative data, medical conditions, prescriptions, laboratory results and registries associated with outpatient visits and diagnoses coded according to the International Classification of Diseases, 10th Revision (ICD-10). This electronic clinical record system will be used to classify vaccination status as well as to identify comorbidities or underlying conditions in cohort members and establish baseline characteristics of the cohort at study start.

During the study period, the primary care electronic registries of the nine participating PCCs will be used as a data source to identify those subjects who have suffered any study event that did not require hospitalisation and were treated as an outpatient during the 30-month study period.

Emergence and hospital diagnosis discharge databases of two reference hospitals (coded according to ICD-9-CM codes (International Classification of Diseases, 9th Revision, Clinical Modification) will be used to identify those cohort members who were admitted to hospital for any study event during the 30-month study period.

A structured data collection instrument will be used to review primary care and hospital clinical records to validate the diagnosis of all cases initially identified by ICD-10 or ICD-9 discharge codes.

Main outcomes and definitions

The primary endpoints of the *CAPAMIS Study* will be the occurrence of CAP (hospitalised or outpatient), hospitalisation for AMI, stroke and death from any cause. Table 1 shows definitions and criteria used in collecting primary and secondary outcomes.

The occurrence of CAP will be established on the basis of an acute respiratory illness, with evidence of the presence of a new infiltrate in a chest radiograph.

Outpatient CAP will be identified from primary care or emergency visit (not hospitalised) with a code registered for pneumonia in the PCCs diagnoses databases (ICD-10 codes: J10.9, J11.9, J12 to J18) or in Emergency discharge databases (ICD-9-CM codes: 480 to 487.0). Hospitalisations for CAP will be identified on the basis of the listed primary diagnosis codes in the hospital discharge databases (ICD-9-CM codes 480 to 487.0).

All cases of CAP (hospitalised and outpatient) must be radiographically confirmed and validated by checking the clinical record with the use of a standardized data-collection instrument (which includes sociodemographical,




Figure 1 Research areas of the CAPAMIS Study. This figure illustrates the geographical distribution of the nine participating Primary Health Care Centers in the region of Tarragona (a mixed residential-industrial urban area, which is located 95 Km from Barcelona, in the mediterranean coast of Catalonia, Spain).

clinical, exploratory, analytical and radiographical data at the time of diagnosis). CAP will be considered if, on conclusion of the medical record review, the physician reviewer verified this diagnosis and it was not a readmission, a nosocomial pneumonia or another diagnosis. Pneumonia severity index (PSI) and the simpler severity rule CURB-65 will be calculated according to criteria described in classical studies [38,39].

Hospitalisation for AMI will be initially identified on the basis of listed primary and secondary diagnosis codes in the reference hospital discharge database (ICD-9-CM code: 410).

Hospitalisation for stroke will also be initially identified on the basis of the listed primary and secondary

diagnosis codes in hospital discharge databases (ICD-9-CM codes 430 to 437). Ischaemic strokes (codes 433, 434, 436 or 437) and hemorrhagic strokes (codes 430 to 432) will be considered, but transient ischemic attacks (code 435) will be excluded for the analyses.

All cases of AMI and stroke will be further validated by checking hospital medical records with a standardized data-collection instrument that includes clinical characteristics of the events, and they will be classified as "CAP-related" (occurring within 30 days after onset of pneumonia) or "CAP-nonrelated" (occurring more than 30 days after an episode of pneumonia or occurring among patients who have not suffered a previous CAP).

Table 1 Definitions and criteria used to identify and classify the different endpoints in the CAPAMIS Study.

OUTCOMES	DEFINITIONS
A. Community-acquired pneumonia (CAP)*	Pneumonia will be considered when a new radiological infiltrate is identified in a patient with one major criterion (cough, expectoration or fever) or two minor criteria (dyspnea, pleuritic pain, altered mental status, pulmonary consolidation on auscultation and leukocytosis).
A1. Hospitalised CAP	Will be considered those pneumonia cases identified on the basis of the listed primary diagnosis codes in hospital discharge databases (ICD-9-CM codes for pneumonia: 480 to 487.0).
A2. Outpatient CAP	Will be considered those CAP cases non-hospitalised, and they will be identified from primary care or emergency visits (not hospitalised) with a code registered for pneumonia in the Emergency Unit discharge codes databases (ICD-9-CM codes: 480 to 487.0) or Primary Care Centers diagnosis database (ICD-10 codes: J10.9, J11.9 and J12 to J18).
B. Pneumococcal CAP**	Defined as a patient with CAP from whom <i>Streptococcus Pneumoniae</i> is identified by blood culture, sputum culture or urinary antigen.
B1. Bacteremic pneumococcal CAP	Will be considered when <i>S. pneumoniae</i> was isolated from blood specimens or other sterile sites.
B2. Nonbacteremic pneumococcal CAP	Will be considered when the patients have a typical clinical syndrome of pneumonia without bacteremia (negative or not performed blood culture), but they have a sputum culture that yielded pneumococci with no other likely bacterial pathogens and/or they have positive Binax-NOW <i>Streptococcus pneumoniae</i> urinary antigen test.
C. Acute myocardial infarction (AMI)	Defined as a patient hospitalised with diagnosis of acute or recurrent episode of myocardial infarction. Cases will be identified on the basis of the primary and secondary listed diagnosis codes in the hospital discharge database (ICD-9-CM code for AMI: 410). All initially identified cases of AMI will be further validated by checking hospital medical records, and each case will be classified as related or nonrelated with a prior episode of CAP.
C1. CAP-related episode of AMI	Defined as AMI occurring within the first 30 days after the onset of an episode of CAP.
C2. CAP-nonrelated episode of AMI	Case of AMI occurring more than 30 days after an episode of CAP or in a patient without history of prior CAP.
D. Hospitalisation for stroke	Defined as a patient admitted to hospital with a diagnosis of stroke, ictus or cerebral infarction. Cases will be identified on the basis of the primary and secondary listed diagnosis codes in the hospital discharge databases (ICD-9-CM codes for stroke: 430 to 437). Haemorrhagic strokes (codes 430 to 432) and ischaemic strokes will be considered (codes 433, 434, 436 or 437), but transient ischaemic attacks (code 435) will be excluded for the analyses. All cases initially identified of stroke will be further validated by checking hospital medical records, and each case will be classified as related or nonrelated with a prior episode of CAP.
D1. CAP-related episode of stroke	Defined as an episode of stroke occurring within the first 30 days after the onset of CAP.
D2. CAP-nonrelated episode of stroke	Defined as an episode of stroke occurring more than 30 days after an episode of CAP or in a patient without history of a prior episode of CAP.
E. All-cause death	It includes patients who died for any cause during the study period. Cases will be identified from primary care information system of each participating PCC.
E1. Death from CAP	Defined as a patient who died (in hospital or not) within the first 30-days after the onset of CAP.
E2. Death from AMI	Defined as a patient who died within hospital stay or within the first 30-days after the diagnosis of AMI.
E3. Death from stroke	Defined as a patient who died within hospital stay or within the first 30 days after the onset of the stroke.

* All cases of CAP (hospitalised and outpatient) must be radiographically confirmed and validated by checking the clinical record with the use of a standardized data-collection instrument. CAP will be considered if, on conclusion of the medical record review, the physician reviewer verified this diagnosis and it was not a readmission, nosocomial pneumonia or another diagnosis.

** Pneumococcal CAP will initially be identified on the basis of ICD-9-CM codes for pneumococcal bacteraemia (codes 038.0, 038.2, 041.0, 041.2) or pneumococcal pneumonia (code 481) in the Hospitals and Emergency discharge diagnosis databases and ICD-10 code for pneumococcal pneumonia (code J13) in the Primary Care visits diagnosis databases. Laboratory records will also be used to identify cases of pneumococcal infections not detected in ICD-9-CM or ICD-10 discharge codes.

Because of the size of the study, an active following of study participants is not feasible. Nevertheless, the nine PCCs and two reference hospitals provide daily care to the inhabitants living in the selected study area, and they basically apply similar diagnostic checklist and treatment for patients presenting with a clinical suspicion of pneumonia, myocardial infarction or cerebrovascular accident.

Vaccination history

Vaccination status of cohort members will be determined by a review of the PCCs' electronic clinical

records, which contain specially designated fields for pneumococcal and influenza vaccinations. We assume that information in clinical records is complete, so a subject will be considered as unvaccinated when a vaccination was not recorded in the PCC clinical record.

Pneumococcal vaccination status (including number of dose of PPV-23 received in prior 10 years) will be determined at study start and it will be reevaluated at the end of the first and second year of the study period. Similarly, influenza vaccination status will be determined

Table 2 Definitions and criteria used to collect respiratory and cardiovascular risk factors and main comorbidities among cohort members in the CAPAMIS Study.*

UNDERLYING CONDITIONS	DEFINITIONS
History of prior pneumonia	Includes influenza-related pneumonia (J10.0 and J11.0), viral pneumonia (J12), pneumococcal pneumonia (J13), pneumonia due to <i>Haemophilus influenzae</i> (J14), bacterial pneumonia (J15), pneumonia due to other infectious organisms (J16), pneumonia in diseases classified elsewhere (J17) and pneumonia due to unspecified microorganisms (J18).
History of coronary artery disease	Includes angina (I20), acute myocardial infarction (I21), subsequent or recurrent myocardial infarction (I22) and chronic ischaemic heart disease (I25).
History of stroke	Includes haemorrhagic stroke (I60 to I62), cerebral infarction (I63) and stroke not specified as haemorrhage or infarction (I64); it does not include transient ischaemic attacks (code G45).
Hypertension	Defined as the presence of any code I10, I11, I12, I13 or I15.
Hypercholesterolemia	Defined as the presence of code E78.
Diabetes mellitus	Codes E10 to E14.
Obesity	Patients with registered code E66 (BMI>30%).
Smoking	Includes patients with current smoking (code F17 active at study start).
Alcoholism	Includes patients with code F10 active at study start.
History of heart disease	Includes congestive heart failure (I50), hypertensive heart disease (I11), cardiomyopathy (I42), cardiac dilatation or ventricular hypertrophy (I11.9 or I51.7) and coronary artery disease (I20, I21, I22 and I25).
History of vascular ischaemia	Besides coronary artery disease and stroke, it includes atherosclerosis (I70), acute arterial embolism or thrombosis (I74) and peripheral arterial disease or intermittent claudication (I73.9).
Chronic pulmonary disease	Includes chronic bronchitis or emphysema (J42 to J44) and asthma: (J45).
Severe liver disease	Includes chronic viral hepatitis (B18), alcoholic hepatitis (K70) and cirrhosis (K74).
Severe nephropathy	Includes nephrotic syndrome (N04 or N39.1), renal failure (N18, N19) and kidney dialysis (Y84.1) or transplantation.
Immunocompromise	Defined as the presence of any immunodeficiency (D80 to D84), AIDS (B20 to B24), anatomic or functional asplenia (D73.0 and Q89.0), cancer, severe nephropathy, or long-term corticosteroid therapy (20 mg/day of prednisone or equivalent).

* Data will be considered at the beginning of the study, and it will be defined according to the International Classification of Diseases 10th Revision (ICD-10) codes registered in the primary care clinical record of each cohort member at the start of the study.

at the beginning of the study (according to reception or not of a dose of flu vaccine in prior autumn) and it will also be reevaluated every year of the study period.

Covariates

Covariates will be age, sex, frequency of attendance (number of outpatient visits per year), history of pneumonia in 24-month before study start, history of coronary artery disease, history of prior stroke, presence of major cardiovascular risk factors (hypertension, hypercholesterolaemia, smoking, diabetes mellitus or obesity), presence of major comorbidities (chronic heart disease, chronic pulmonary disease, severe liver disease, chronic nephropathy or cancer) and immunological status. Table 2 lists covariates and shows criteria used to measure and capture underlying conditions and comorbidities in the study cohort.

Statistical analysis

Absolute numbers, means and percentages will be computed to describe the patient population. The differences between groups will be evaluated using the chi-squared or Fisher's test for categorical variables, and the two tailed Student's test or ANOVA for continuous variables as appropriate.

The crude association between the outcomes and vaccination will be evaluated using incidence rates among vaccinated and unvaccinated subjects. The incidence of each event will be calculated as person-year considering in the denominator the sum of person-time contributed to each individual during study period.

Multivariable Cox proportional hazards models with time-varying covariates will be used to calculate hazards ratio (HR) and estimate the association between having received the pneumococcal vaccine and the time of the first outcome event during the study period. Repeated episodes will not be included in the analyses. Vaccine effectiveness will be estimated as $(1 - HR) \times 100$.

Pneumococcal vaccination status will be a time-varying condition (e.g., individuals vaccinated after the beginning of the study) and persons will be considered to be vaccinated 14 days after vaccine administration. Annual influenza vaccine status will also be a time-varying covariate, whereas the other covariates will be defined at study start.

It will be checked for confounders, interactions and multicollinearity among the independent variables. The final models will be adjusted by all significant variables, as well as confounders and other baseline covariables judged of having clinical importance. The proportional hazards assumptions will be assessed adding the covariate by log-time interactions to the model and plotting the scaled and smoothed Schoenfeld residuals obtained

from main effects model was possible [40]. Statistical significance will be set at $p < 0.05$ (two-tailed). The analyses will be performed using Stata/SE Version 9.1. (Stata Corp.)

Ethical concerns

The study protocol has received ethics approval by the ethical committee of clinical research of the IDIAP Jordi Gol Foundation of the *Catalonian Health Institute* (ID P09/49) and it will be conducted in accordance with the general principles for observational studies.

The study protocol has received ethics approval by the ethical committee of *Catalonian Health Institute* (ID: CEIC IDIAP J. Gol P09/49) and it will be conducted in accordance with the general principles for observational studies. Given this is a non-interventional study, an informed consent for all 27000 study participants will not be required, but consent will be obtained to review clinical records of those cohort members who suffer any study event during follow-up.

Discussion

The clinical effectiveness of the PPV-23 is controversial, especially in preventing some outcomes such as CAP or AMI. However, given the demonstrated effectiveness of the vaccine in protecting individuals against IPD, commencing new randomised clinical trials in populations at risk where vaccine effectiveness and disease burden is known would create ethical difficulties. Thus, cohort studies are an acceptable alternative to estimate vaccine effectiveness against different pneumococcal-related outcomes among different populations at risk.

To our knowledge, this population-based cohort study in adults aged 60 years or older is the first large prospective study planned to evaluate the possible clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke, related or not with prior episodes of pneumonia.

The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be important to determine the possible role of pneumococcal vaccination in cardiovascular prevention.

This study has been conceived and designed to investigate the clinical effectiveness of the PPV-23 against pneumonia and acute cardiovascular events. Nevertheless, in addition to the primary objectives of the study, several substudy objectives are currently under development to maximise opportunities to learn about the health conditions in this older adult population-based cohort.

Acknowledgements

The project is financially supported by a grant from the *Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III, Spanish Ministry of Health* (grant ID: FIS PS-09/00043).

Thanks to Dolors Rovira Veciana, Timothy Bowring and Claustra Iglesias for their assistance on the production of this paper.

Author details

¹Primary Care Service of Tarragona-Valls, Institut Català de la Salut, Tarragona, Spain. ²Department of Microbiology and Laboratory, Hospital Santa Tecla, Tarragona, Spain. ³Department of Medicine and Surgery, Faculty of Medicine and Health Sciences, Rovira i Virgili University, Tarragona, Spain.

Authors' contributions

AVC wrote the research proposal which was approved by the *Instituto de Salud Carlos III* for funding; I. Hospital, CD, ES, XR and CMF conducted data collection; AVC and OO supervised the data collection; AVC wrote the draft of the manuscript; all authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 16 November 2009

Accepted: 19 January 2010 Published: 19 January 2010

References

1. Ortvist A, Hedlund J, Kalin M: *Streptococcus pneumoniae*: epidemiology, risk factors, and clinical features. *Semin Respir Crit Care Med* 2005, **26**(6):563-74.
2. Hausdorff WP, Feikin DR, Klugman KP: *Epidemiological differences among pneumococcal serotypes*. *Lancet Infect Dis* 2005, **5**:83-93.
3. Bartlett JG, Mundy LM: *Community-acquired pneumonia*. *N Engl J Med* 1995, **24**:1618-1624.
4. Marrie TJ: *Community-acquired pneumonia in the elderly*. *Clin Infect Dis* 2000, **31**:1066-78.
5. Zalacain R, Torres A, Celis R, Blanquer J, Aspa J, Esteban L, Menéndez R, Blanquer R, Borerías L: *Community-acquired pneumonia in the elderly: Spanish multicentre study*. *Eur Respir J* 2003, **21**(2):294-302.
6. Centers for Disease Control and Prevention: *Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practice (ACIP)*. *MMWR Morb Mortal Wkly Rep* 1997, **46**(RR-8):1-24.
7. Fedson DS, Musher DM: *Pneumococcal polysaccharide vaccine*. *Vaccines Philadelphia: SaundersPlotkin SA, Orenstein WA*, 4 2003, 529-88.
8. Fedson DS: *Pneumococcal vaccination for older adults: the first 20 years*. *Drugs Aging* 1999, **15**(Suppl 1):21-30.
9. Vila-Corcoles A: *Advances in pneumococcal vaccines: what are the advantages for the elderly?*. *Drugs Aging* 2007, **24**:791-800.
10. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, Detsky AS, Kapoor WN: *Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials*. *Arch Intern Med* 1994, **154**:2666-77.
11. Moore RA, Wiffen PJ, Lipsky BA: *Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials*. *BMC Fam Pract* 2000, **1**:1.
12. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M: *Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials*. *Vaccine* 2001, **19**:4780-90.
13. Puig-Barberà J, Belenguer Varea A, Goterris Pinto M, Brines Benlliure MJ: *Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis*. [In Spanish]. *Aten Primaria* 2002, **30**:269-81.
14. Mangtani P, Cutts F, Hall AJ: *Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence*. *Lancet Infect Dis* 2003, **3**:71-8.
15. Watson L, Wilson BJ, Waugh N: *Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults*. *Vaccine* 2002, **20**:2166-73.
16. Melegaro A, Edmunds WJ: *The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: comparison of meta-analyses*. *Eur J Epidemiol* 2004, **19**:353-63.
17. Fedson DS, Liss C: *Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults*. *Vaccine* 2004, **22**:927-46.
18. Moberley SA, Holden J, Tatham DP, Andrews RM: *Vaccines for preventing pneumococcal infection in adults*. *Cochrane Database Syst Rev* 2008, **1**: CD000422.

19. Huss A, Scott P, Stuck AE, Trotter C, Egger M: **Efficacy of pneumococcal vaccination in adults: a meta-analysis.** *CMAJ* 2009, **180**:48-58.
20. Vila-Corcoles A: **Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia?** *Lancet Infect Dis* 2008, **8**:405-6.
21. Hansson GK: **Inflammation, atherosclerosis, and coronary artery disease.** *N Engl J Med* 2005, **352**:1685-95.
22. Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, Filippov AE, Casscells SW: **Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects.** *Eur Heart J* 2007, **28**:1205-10.
23. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P: **Risk of myocardial infarction and stroke after acute infection or vaccination.** *N Engl J Med* 2004, **351**(25):2611-8.
24. Ramirez J, Aliberti S, Mirsaedi M, Peyrani P, Filardo G, Amir A, Moffett B, Gordon J, Blasi F, Bordon J: **Acute Myocardial Infarction in Hospitalized Patients with Community-Acquired Pneumonia.** *Clin Infect Dis* 2008, **47**:182-7.
25. Musher DM, Rueda AM, Kaka AS, Mapara SM: **The association between pneumococcal pneumonia and acute cardiac events.** *Clin Infect Dis* 2007, **45**:158-65.
26. Lamontagne F, Garant MP, Carvalho JC, Lanthier L, Smieja M, Pilon D: **Pneumococcal vaccination and risk of myocardial infarction.** *CMAJ* 2008, **179**(8):773-7.
27. Madjid M: **Acute infections, vaccination and prevention of cardiovascular disease.** *CMAJ* 2008, **179**(8):749-50.
28. Vila-Corcoles A: **Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination.** *J Intern Med* 2009, **266**:432-44.
29. Binder CJ, Binder CJ, Hökkö S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ: **Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between streptococcus pneumoniae and oxidized LDL.** *Nat Med* 2003, **9**:736-43.
30. Martin GM: **Atherosclerosis is the leading cause of death in the developed societies.** *Am J Pathol* 1998, **153**:1319-20.
31. Vila-Corcoles A, Ochoa-Gondar O, Ester F, Sarrá N, Ansa X, Saún N, EVAN Study Group: **Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalan older adults: 4-years follow-up.** *BMC Public Health* 2006, **6**:231.
32. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, Llor C, EVAN Study Group: **Protective Effects of the 23-Valent Pneumococcal Polysaccharide Vaccine in the Elderly Population.** *Clin Infect Dis* 2006, **43**:860-8.
33. Vila-Corcoles A, Salsench E, Rodríguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, Hospital I, Gomez-Bertomeu F, Raga X: **Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.** *Vaccine* 2009, **27**:1504-10.
34. Ochoa-Gondar O, Vila-Córcoles A, de Diego C, Arija V, Maxenchs M, Grive M, Martín E, Pinyol JL, EVAN-65 Study Group: **The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study.** *BMC Public Health* 2008, **8**:222.
35. Vila-Córcoles A, Ochoa-Gondar O, Rodríguez-Blanco T, Raga-Luria X, Gómez-Bertomeu F, EPIVAC Study Group: **Epidemiology of community-acquired pneumonia in older adults: a population-based study.** *Respir Med* 2009, **103**:309-16.
36. Novella B, Alonso M, Rodríguez-Salvanés F, Susi R, Reviriego B, Escalante L, Suárez C, Gabriel R: **Ten-year incidence of fatal and non-fatal myocardial infarction in the elderly population of Madrid. [In Spanish].** *Rev Esp Cardiol* 2008, **61**(11):1140-9.
37. Díaz-Guzmán J, Díaz-Guzmán J, Egado-Herrero JA, Fuentes B: **Incidence of strokes in Spain: the Iberictus study. Data from the pilot study [in Spanish].** *Rev Neurol* 2009, **48**(2):61-5.
38. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: **A prediction rule to identify low-risk patients with community-acquired pneumonia.** *N Engl J Med* 1997, **336**(4):243-250.
39. Lim WS, Eerden van der MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: **Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.** *Thorax* 2003, **58**(5):377-382.
40. Hosmer DW, Lemeshow S: **Applied Survival Analysis. Regression Modeling of Time to Event Data.** New York: John Wiley & Sons 1999, 159-80.

Pre-publication history

The pre-publication history for this paper can be accessed here:<http://www.biomedcentral.com/1471-2458/10/25/prepub>

doi:10.1186/1471-2458-10-25

Cite this article as: Vila-Corcoles et al.: Rationale and design of the CAPAMIS study: Effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. *BMC Public Health* 2010 **10**:25.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

